BCM
GOSS icon

Beaumont Capital Management’s Gossamer Bio GOSS Stock Holding History

Beaumont Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64K Buy
276
+141
+104% +$3.15K ﹤0.01% 34
2026
Q1 		$3.54K Buy
+135
New +$17K ﹤0.01% 32

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Beaumont Capital Management's GOSS Position: Q2 2026 in Review

Beaumont Capital Management increased its Gossamer Bio (GOSS) stake by 104% in Q2 2026, buying an estimated $3.15K and bringing the position to 276 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #34.

Beaumont Capital Management first reported a position in GOSS in Q1 2026 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Beaumont Capital Management held 276 shares of Gossamer Bio worth $3.64K as of Q2 2026.
  • Beaumont Capital Management bought 141 Gossamer Bio shares in Q2 2026, an estimated $3.15K.
  • Gossamer Bio made up ﹤0.01% of Beaumont Capital Management's portfolio in Q2 2026, its #34 holding.
  • Beaumont Capital Management first reported a position in Gossamer Bio in Q1 2026 and has held it in 2 quarters since.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Beaumont Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.